These results suggest that the canonical inflammasome pathway probably plays a more prominent role in vascular inflammation and lesion development in ApoE−/− mice, and that the novel human GSDMD inhibitor, Ac-FLTD-CMK, may be a novel and effective drug to treat atherosclerosis in the future. Here, APOE is linked to atherosclerosis.